Cloverleaf Bio

Cloverleaf Bio develops an RNA therapeutic platform for oncology.

Health and bio

Cloverleaf Bio raised $33M in a Seed round announced September 8, 2026, according to hartfordbusiness.com. Investors in that round: 4BIO Capital, AbbVie, Boehringer Ingelheim Venture Fund, BrightEdge - American Cancer Society, Draper Associates, Eli Lilly, Mission BioCapital.

Founders and team

• AD
  Austin Draycott Founder

  source: crunchbase.com
• CL
  Cole Lewis Founder

  source: crunchbase.com
• WV
  Wendy V. Gilbert Founder

  source: crunchbase.com
• CV
  Christina Vorvis Board member

  source: crunchbase.com
• DK
  Dima Kuzmin Board member

  source: crunchbase.com

Raise history

1. September 8, 2026
   Seed · $33M
   44BIO Capital (lead), AAbbVie, BBoehringer Ingelheim Venture Fund, BBrightEdge - American Cancer Society, DDraper Associates, EEli Lilly, MMission BioCapital
   Source: hartfordbusiness.com
2. January 19, 2023
   X account created

Investors

• 44BIO Capital
• AAbbVie
• BBoehringer Ingelheim Venture Fund
• BBrightEdge - American Cancer Society
• DDraper Associates
• EEli Lilly
• MMission BioCapital

Related bio health companies

• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/cloverleaf-bio.